Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

IntelGenx Technologies Corp. (IGXT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1211-0.0209 (-14.70%)
At close: 03:37PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1420
Open0.1400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1200 - 0.1400
52 Week Range0.1100 - 0.6500
Volume444,758
Avg. Volume116,922
Market Cap18.57M
Beta (5Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0650
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

    SAINT LAURENT, Quebec, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) has reached the halfway mark. This proof-of-concept study currently includes six clinical research sites with the potential of adding two more sites in the coming month, all of which are expected to

  • GlobeNewswire

    IntelGenx Reports Second Quarter 2022 Financial Results

    SAINT LAURENT, Quebec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. 2022 Second Quarter Financial Summary: Revenue was $398,000, compared to $1

  • GlobeNewswire

    IntelGenx to Report Second Quarter 2022 Financial Results on August 11, 2022 – Conference Call to Follow

    SAINT LAURENT, Quebec, Aug. 04, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2022 financial results after market close on Thursday, August 11, 2022. An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer, to discuss the results and provide a business update. Detai

Advertisement
Advertisement